A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors

J. Alexandre,Carmen Kahatt,Frédérique Bertheault-Cvitkovic,S. Faivre,Stephen Shibata,Werner Hilgers,François Goldwasser,François Lokiec,Eric Raymond,G. Weems,Shah A,John R. MacDonald,Esteban Cvitkovic

A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors

2007

J. Alexandre
Carmen Kahatt
Frédérique Bertheault-Cvitkovic
S. Faivre
Stephen Shibata
Werner Hilgers
François Goldwasser
François Lokiec
Eric Raymond
G. Weems
Shah A
John R. MacDonald
Esteban Cvitkovic

Purpose To determine the maximum tolerated dose (MTD), recommended dose, dose limiting toxicities (DLT), safety and pharmacokinetics of irofulven combined with capecitabine in advanced solid tumor patients.

Keywords:

Drug interaction
Capecitabine
Irofulven
Advanced Solid Tumor
Febrile neutropenia
Maximum tolerated dose
Dose-Limiting
Oncology
Pharmacokinetics
Internal medicine
Medicine
dose limiting toxicity
in patient
pharmacology toxicology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations